Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19.

Jyoti ShakrawalVidhu SharmaAmit GoyalDeepak KumarSeema MeenaSarbesh TiwariVidhi JainPoonam ElhenceKapil SoniBikram ChoudhuryKavita BhatnagarMahendra Kumar GargSanjeev Misra

Published in: International ophthalmology (2022)

TRAMB, as an adjuvant to standard systemic antifungal therapy, is associated with a significant reduction or stabilisation of orbital involvement. TRAMB should be considered as an adjuvant therapy for ROCM to reduce disease progression as well as to preserve globe or sight. It has a promising role in preventing potential orbital exenterations.

Keyphrases

early stage
coronavirus disease
candida albicans
metabolic syndrome
climate change
insulin resistance
glycemic control
blood brain barrier